Prosecution Insights
Last updated: November 20, 2026
Application No. 19/110,125

USE OF AN ALKYLETHER SULFATE FOR IMPROVING THE EFFICACY OF HERBICIDES

Non-Final OA §103§112§DP
Filed
Mar 10, 2025
Priority
Sep 14, 2022 — provisional 63/406,551 +2 more
Examiner
STEVENS, MARK V
Art Unit
1613
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
BASF SE
OA Round
1 (Non-Final)
66%
Grant Probability
Favorable
1-2
OA Rounds
11m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 66% — above average
66%
Career Allowance Rate
577 granted / 881 resolved
+5.5% vs TC avg
Strong +41% interview lift
Without
With
+41.4%
Interview Lift
resolved cases with interview
Typical timeline
2y 8m
Avg Prosecution
50 currently pending
Career history
951
Total Applications
across all art units

Statute-Specific Performance

§101
5.1%
-34.9% vs TC avg
§103
39.8%
-0.2% vs TC avg
§102
11.7%
-28.3% vs TC avg
§112
23.9%
-16.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 881 resolved cases

Office Action

§103 §112 §DP
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Status Claims 1-19 are pending and under examination. Priority This application is a national stage entry of PCT/EP2023/074592 filed on 9/7/2023, which claims priority to US provisional application 63/406,551 filed on 9/14/2022 and EP22198428.9 filed on 9/28/2022. Information Disclosure Statement The information disclosure statement filed on 8/1/2025 has been considered by the examiner. Claim Objections Claim 1 is objected to for “one or more herbicidal compound” which should be “one or more herbicidal compounds” for grammatical sense. Claim 2 is objected to as applicant provides “are applied”, but should recite a structure such as “A method for controlling undesired plants comprising applying at least one compound of formula (I)……. and at least one herbicide compound to the undesired plants or their habitat.” to correctly provide the step of “applying”. Claims 16 and 17 are objected to for additional periods after i and ii in the claim where one period is allowed per claim unless for a decimal point or acceptable abbreviation. Applicant may recite these as i) and ii) instead. Claim 11 is objected to for missing the word “or” between “decoupler herbicides;” and “(o) other herbicides….” Claim 11 is objected to for recitations of dymron, which is more appropriately “daimuron”. Claim 11 is objected to for the recitations of the CAS numbers in the claim (item (o)). Applicant should just utilize named chemical compound as provided outside the parenthetical. Claim 19 is objected to for “is elected”, which should be “is selected”. Appropriate correction is required. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1, 5-8, 10-15 and 19 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1 is indefinite for “comprising use of at least one compound” in this method claim without setting forth the action in what “use of” does to perform the method. Applicant may consider replacing “use of” with “adding” or “contacting” and after the compound definition including “with one or more herbicidal compounds.” Claim 5 is indefinite for providing a new “n” in one of the R1 groups of the list and then defining that n as 0, 1 or 2 when claim 2, on which claim 5 depends, already has a definition for “n”, which is in a range of 1 to 10. Thus, it is unclear that applicant is redefining n in all senses of its use in the claims or if the definition of n in claim 5 is independent from what is provided for n in claim 2. Applicant may consider calling the “n” in claim 5 as a different letter or perhaps “ n’ “. Claims 6-8 are rejected for being dependent on an indefinite claim. Claim 10 is indefinite for “A is a CH2CH2 or a combination of CH2CH2 and CH2CH(CH3)” since if A was a combination of CH2CH2 and CH2CH(CH3), it would provide a group having C5 which is more than what A allows for carbons. It is unclear if applicant means the combination to allow for such a combined group or if applicant means to say “A is CH2CH2 or CH2CH(CH3)” or if applicant is allowing for A to be different for each (A-O)n group when n is an integer from 2 to 10. Applicant should clarify the claim, but for the purpose of compact prosecution, the examiner will consider the A can be the combination option when n is 2 to 10. Claim 11 recites the limitations "the glutamine synthetase inhibitors", “the enolpyruvyl shikimate 3-phosphate synthase inhibitors”, “the synthesis of very long chain fatty acids” in the claim with no first recitation of “glutamine synthetase inhibitors”, enolpyruvyl shikimate-3-phosphate synthase inhibitors” and “synthesis of very long chain fatty acids”. There is insufficient antecedent basis for this limitation in the claim. A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) may be considered indefinite if the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP § 2173.05(c). In the present instance, claim 11 recites the broad recitation “lipid biosynthesis inhibitors”, and the claim also recites (acetyl-CoA carboxylase inhibitors, ACCase inhibitors), which is the narrower statement of the range/limitation. The claim(s) are considered indefinite because there is a question or doubt as to whether the feature introduced by such narrower language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. Claim 11 is indefinite for “inhibitors of the synthesis of very long chain fatty acids (VLCFA inhibitors)” as what is in parentheticals does not indicate these have to be “synthesis inhibitors” and so the meaning of what is in parentheticals could be to various other inhibitors involving VLCFA signaling. Applicant may remove the parenthetical or provide it as (VLCFA synthesis inhibitors) so that it is a proper abbreviation. Claim 11 is indefinite for “oleic acid” as an herbicide in the group (o). It is not clear that oleic acid has herbicidal activity by the art and how it would fit as being an herbicide compound. Applicant may remove oleic acid from the group. Claim 11 is indefinite for “methyl iodide” as an herbicide in the group (o). Although methyl iodide is used for controlling pests/insects/bacteria/fungi, it does not appear to be known in the art as an herbicide/weed control agent. Applicant may remove methyl iodide from the group or provide evidence of its use as an herbicide. Claim 11 is indefinite for DSMA and MSMA as the claim nor the specification provides what they are abbreviations for. Thus, it is unclear how these abbreviations should be read in the claim and unclear if applicant has support for what they might be. A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) may be considered indefinite if the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP § 2173.05(c). In the present instance, claim 11 recites the broad recitation (HST-inhibitor, FMC), and the claim also recites “6-chloro-4-(2,7-dimethyl-1-naphthyl)-5-hydroxy-2-methyl-pyridazin-3-one”, which is the narrower statement of the range/limitation. The claim(s) are considered indefinite because there is a question or doubt as to whether the feature introduced by such narrower language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. Claims 11-15 and 19 recite the limitation "the herbicide compound" in the claims with dependence to claim 2, which introduces the limitation as “at least one herbicide compound”. There is insufficient antecedent basis for this limitation in the claim. Applicant may recite the limitation in these claims as “the at least one herbicide compound…” Claims 14-15 recite the limitation "the compound of formula (I)" in the claims with dependence to claim 2, which introduces the limitation as “at least one compound of the formula (I)”. There is insufficient antecedent basis for this limitation in the claim. Applicant may recite the limitation in these claims as “the at least one compound of the formula (I)….” Claims 12, 13 and 19 recite the limitations "the group (a)”, “groups (b) to (o)” and “group a” and in the claims with dependence (direct or indirect) to claim 2, which does not introduced these groups. There is insufficient antecedent basis for this limitation in the claim. It appears that claim 12 should be dependent on claim 11 for the claims to make sense. Claim Rejections – 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1 and 16-18 are rejected under 35 U.S.C. 103 as being unpatentable over Long US 20190110469A1. Long teaches a liquid herbicidal composition that includes glufosinate and/or a salt thereof and an alkyl ether sulfate or a salt thereof (abstract). Long teaches the alkyl ether sulfate as R—(OCH2CH2)n—OSO4 (I), wherein R is linear or branched alkyl group having from 8 to 18 carbon atoms and wherein the subscript n ranges from 1 to 10 (abstract, also see paragraphs 17-22). Paragraph 19, teaches sodium or potassium salts (paragraph 19). Paragraphs 57-58 provides another water soluble herbicidal component such as isopropylatnmonium glyphosate, or of potassium aminophosphate or aminophosphonate salt, such as potassium glyphosate salt. Long teaches glufosinate ammonium in table 1. Long teaches 10 to 30 wt% of glufosinate or a salt thereof (claim 4 of Long). Long teaches 20 to 30 wt% of alkyl ether sulfate (claim 16 of Long). Thus, Long provides for 1:1 to 3:1 weight ratios of alkyl ether sulfate to glufosinate herbicidal compound. Long teaches diluting the composition with water in a spray tank prior to applicant, which allows for tank mixed (paragraph 53). Note an aqueous spray liquor is a formulation that has been diluted with water. Long teaches a procedure of adding the ingredients to a mixing vessel with mixing in each ingredient (paragraphs 65-72). Long teaches a stable glufosinate soluble liquid formulation (paragraph 73). Long does not teach a specific compound with an R group as on applicant’s claimed compound of formula (I) where R is a branched C10 alkyl, but Long does allow for branched alkyls of 8 to 18 carbon atoms. One of ordinary skill in the art before the time of filing would have worked within the alkyl ether sulfate salts provided by the group in Long to provide formulations that combine a glufosinate or salt thereof with such an alkyl ether sulfate salt having a branched C10 alkyl group since the range of 8 to 18 carbon includes 10. There would have been a reasonable expectation of success in providing the claimed formulations through the teachings of Long’s formulations. In producing such formulations through combination of glufosinate and the alkyl ether sulfate salt(s), increased herbicidal effectiveness (an activity of the composition) would occur. Claims 2-15 and 19 in addition to Claims 1 and 16-18 are rejected under 35 U.S.C. 103 as being unpatentable over Long US 20190110469A1 and Baur US20080045415A1. Long teaches the claims as discussed above. Long also teaches use of branched alkyl ether sulfates along with glufosinate herbicide. Long teaches the alkyl ether sulfate as R—(OCH2CH2)n—OSO4 (I), wherein R is linear or branched alkyl group having from 8 to 18 carbon atoms and wherein the subscript n ranges from 1 to 10 (abstract, also see paragraphs 17-22). Long does not teach particular types of branched alkyls for its alkyl ether sulfate, does not teach applying the formulation to undesired plants or their areas, although Long does teach the composition is herbicidal, and does not provide an alkyl ammonia salt of the alkyl ether sulfate as in applicant’s claims. Long does not teach other herbicides for claim 13. Baur teaches “Alkyl ether sulfates having 1 to 9 carbon atoms in the alkyl chain and 1 to 20 alkyleneoxy units in the ether moiety are suitable for use as low-foam additives for enhancing the activity of water-soluble or partially water-soluble agrochemicals” (abstract). Baur teaches suitable alkyl ether sulfates including those with isooctyl or ethylhexyl (paragraph 47) and 2-ethylhexyl (paragraphs 182-191), which are branched chain alkyl. A compound of the formula AI is listed in paragraphs 49-50, which is similar to applicant’s ether sulfate compound besides not having an alkyl with 10 carbons. Baur teaches ratios of active ingredient to alkyl ether sulfate of 1:0.1 to 1:10 (paragraph 267). Baur teaches sprayer liquor (paragraph 266). Baur teaches that the alkyl ether sulfates promote uptake of the active ingredient into the plant (paragraph 265) by virtue of their surfactant properties. Baur teaches a tank mix process (paragraph 264). Baur teaches applying the glufosinate formulations for controlling weeds by applying to land having weeds (paragraphs 299-303, also paragraphs 290-291). Baur teaches ammonium salts of the alkyl ether sulfates (paragraph 202-203). Baur does teach alkanolamine or amine organic salts in paragraph 211. Baur teaches various salt counterions including substituted ammonium ions such as alkylammonium as an organically substituted ammonium ion (paragraph 38). Baur teaches “The formulations of the invention may further also comprise active ingredients of type (b), which are largely insoluble in water, examples being herbicides from the group of the diphenyl ethers such as oxyfluorfen, carbamates, thiocarbamates, triphenyltin compounds and tributyltin compounds, haloacetanilides, phenoxyphenoxyalkanecarboxylic acid derivatives and heteroaryloxyphenoxyalkanecarboxylic acid derivatives, such as quinolyloxy-,quinoxalyloxy-, pyridyloxy-, benzoxalyloxy- and benzothiazolyloxyphenoxyalkanecarboxylic esters, examples being diclofop-methyl, fenoxaprop-ethyl and fenoxaprop-P-ethyl.” (paragraph 18). Diclofop-methyl and fenoxaprop are acetyl CoA carboxylase inhibitors. One of ordinary skill in the art before the time of filing would have combined the teachings of Long with the teachings of Baur in order to produce formulations and methods with branched chain alkyl ether sulfates of applicant’s claims and herbicides such as glufosinate, and reasonably expected alkyl ether sulfates as surfactants would promote the uptake of the active herbicidal ingredients as provided by Baur with a reasonable expectation of success. Although Long does not provide a particular branch structure, it allows for C10 alkyl and Baur notes some branched chain structures on alkyl ether sulfates that would promote such alterations of the alkyl groups with branching. Baur also promotes ammonia and organically modified ammonia counterions for acceptable salts of alkyl ether sulfates. Baur teaches addition of other herbicidal ingredients for such formulations that would be in addition to the glufosinate or salts thereof. Baur teaches the method of using such a formulation with applying it to an area with weeds in need of control. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1 and 16-18 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-4, and 14-16 of U.S. Patent No. 10729129. Although the claims at issue are not identical, they are not patentably distinct from each other because each claim set provides for formulations of branched alkyl ether sulfates of similar formula that can have a C10 alkyl at the R position and be combined with a herbicidal active like glufosinate in aqueous formulations. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to MARK V STEVENS whose telephone number is (571)270-7080. The examiner can normally be reached M-F 9:00 am to 6:00 pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Brian-Yong Kwon can be reached on (571)272-0581. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MARK V STEVENS/Primary Examiner, Art Unit 1613
Read full office action

Prosecution Timeline

Mar 10, 2025
Application Filed
Oct 02, 2026
Non-Final Rejection mailed — §103, §112, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12797410
REDUCTION OF ADVANCED GLYCATION ENDPRODUCTS FROM BODILY FLUIDS
3y 6m to grant Granted Nov 17, 2026
Patent 12778890
DEVELOPMENT OF A NEW FAMILY OF NANOCARRIERS DERIVED FROM NATURAL TETRAMERIC ACID LIPIDS
2y 5m to grant Granted Nov 03, 2026
Patent 12765573
SOFT CANDY WITHOUT FISHY TASTE OR ODOR AND PREPARATION METHOD THEREOF
2y 11m to grant Granted Oct 20, 2026
Patent 12751917
HYDROGELS AS ORAL DELIVERY DOSAGE FORMS, METHODS OF MAKING AND USING SAME
6y 1m to grant Granted Oct 06, 2026
Patent 12751959
CANNABIDIOL NANODRUG FORMULATIONS AND METHODS FOR USE OF THE SAME
3y 4m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
66%
Grant Probability
99%
With Interview (+41.4%)
2y 8m (~11m remaining)
Median Time to Grant
Low
PTA Risk
Based on 881 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month